Literature DB >> 6620304

Mitomycin C analogues with secondary amines at position 7.

B S Iyengar, S M Sami, S E Tarnow, W A Remers, W T Bradner, J E Schurig.   

Abstract

A series of mitomycin C analogues with secondary amines at position 7 was prepared from mitomycin A. Eleven of the 20 new compounds in this series were more active than mitomycin C against P-388 murine leukemia, and 2 of these 11 were significantly less leukopenic. The two substituents conferring these superior properties were 4-formylpiperazine and 2-cyanoaziridine. No quantitative correlations could be made among antitumor activities and physicochemical properties of the analogues, although the relative ease of quinone reduction might be related to the good potencies (minimum effective doses) of many of them.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6620304     DOI: 10.1021/jm00364a018

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.

Authors:  T Tsuruo; Y Sudo; N Asami; M Inaba; M Morimoto
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Cytotoxicity, crosslinking and biological activity of three mitomycins.

Authors:  Shu-Yuan Cheng; Lissette Delgado-Cruzata; Cristina C Clement; Owen Zacarias; Marta Concheiro-Guisan; Nicholas Towler; Timothy Snyder; Maggie Zheng; Nickolas Almodovar; Christina Gonzalez; Marian Romaine; Anne-Marie Sapse; Elise Champeil
Journal:  Bioorg Chem       Date:  2022-03-22       Impact factor: 5.307

3.  Disposition and metabolism of KW-2149, a novel anticancer agent.

Authors:  S Kobayashi; J Ushiki; K Takai; S Okumura; M Kono; M Kasai; K Gomi; M Morimoto; H Ueno; T Hirata
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Cardiotoxicity of mitomycin A, mitomycin C, and seven N7 analogs in vitro.

Authors:  R T Dorr; N G Shipp; J D Liddil; B S Iyengar; K R Kunz; W A Remers
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.

Authors:  T Bando; K Kasahara; K Shibata; Y Numata; U Heki; H Shirasaki; K Iwasa; M Fujimura; T Matsuda
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion.

Authors:  L Dirix; G Catimel; R Verdonk; E De Bruijn; B Tranchand; C Ardiet; A Van Oosterom
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.